Latest News for: btk

Edit

InventHelp Inventor Develops Modified Hospital Bed (BTK-415)

PR Newswire 13 Jul 2026
My design will also help to prevent the strain and possible injuries that are associated with lifting patients." ... 25-BTK-415, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368 ... SOURCE InventHelp. 21% ... .
Edit

InventHelp Inventors Develop New Jet Engine Cover (BTK-441)

PR Newswire 13 Jul 2026
Our design ensures that only fresh air gets directed into engines to help maintain a high level of safety." ... For more information, write Dept. 25-BTK-441, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext ... .
Edit

InventHelp Inventor Develops Home Mail Delivery System (BTK-432)

PR Newswire 13 Jul 2026
PITTSBURGH, July 13, 2026 /PRNewswire/ -- "I am disabled and walk with a cane ... As a result, it saves time and effort ... 25-BTK-432, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext ... .
Edit

InventHelp Inventor Develops New Reel for Winding Tie Wire (BTK-440)

PR Newswire 13 Jul 2026
My design would simplify this type of work to save time and effort for work crews." ... It also increases consistency and convenience ... 25-BTK-440, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368 ... 21% ... .
Edit

An InventHelp 123Invent Client Develops Hunting Product for Attracting Game (BTK-458)

PR Newswire 09 Jul 2026
PITTSBURGH, July 9, 2026 /PRNewswire/ -- "I thought there could be a better way to dangle scented wafers for attracting deer and other game animals when hunting," said an inventor from Ranburne, Alabama ... InventHelp Invention Spotlight ... and Canada ... 21% ... .
Edit

Warm Autoimmune Hemolytic Anemia Market to Observe Stunning Growth at a 14.4% CAGR During the Forecast Period (2026-2036) Due to the Emergence of Novel Drug Classes Such as FcRn Inhibitors, BTK Inhibitors, BAFF-R, and Others | DelveInsight

PR Newswire 30 Jun 2026
Sanofi's WAYRILZ is the first Bruton's Tyrosine Kinase (BTK) inhibitor being developed for immune thrombocytopenia (ITP), with a mechanism aimed at addressing the underlying drivers of disease through broad immune modulation ... BTK Inhibitors Market.
Edit

Argentina and Algeria fans swap jerseys at KC gas station ahead of World Cup match

Kansas City Star 17 Jun 2026
This was a cool moment in Kansas City between an Argentina and Algeria supporter ahead of the World Cup match ... .
Edit

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg,

The Eagle-Tribune 11 Jun 2026
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment ... .
Edit

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses ...

Nasdaq Globe Newswire 11 Jun 2026
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment ... .
Edit

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy (Form 8-K) (Nurix Therapeutics Inc)

Public Technologies 11 Jun 2026
) Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy.
Edit

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader ...

Norfolk Daily News 08 Jun 2026
Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell ... .
Edit

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader ...

Nasdaq Globe Newswire 08 Jun 2026
... collaborate to co-develop and co-commercialise bexobrutideg (NX-5948), Nurix’s investigational Bruton’s Tyrosine Kinase (BTK) degrader.
Edit

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology (Form 8-K) (Nurix Therapeutics Inc)

Public Technologies 08 Jun 2026
Unlike conventional BTK inhibitors which block BTK kinase activity, bexobrutideg harnesses the body's natural protein disposal system (the ubiquitin proteasome pathway) to selectively eliminate BTK ...
Edit

Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma

PR Newswire 04 Jun 2026
LP-168) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) who have received at least two prior systemic therapies, including BTK inhibitors ... BTK inhibitors.
Edit

Demir İpek Yolu'nda dev adım: BTK Hattı tam kapasiteye geçiyor

Istiklal 02 Jun 2026
Tarafsız ve güvenilir habercilik için tıklayın ....

Article Search

tools
×
×
×
×